Map Pharmaceuticals, Inc.

University of South Carolina

Auris Health, Inc.

Sri International

Auris Surgical Robotics, Inc.

Map Pharceuticals, Inc.

Jian Zhang

Robert Owen Cook

Thomas A Armer

Gregory J Kintz

Jeffery B Alvarez

Michael Matthews

Libo Wu

Allan M Quick

David S Mintz

Alan L Yu

Serena H Wong

Enrique Romo

Phillip Andrew Porras

Joseph Bogusky

Steve Burion

Dejian Xie

Sergey Alexandrovich Kosarev

Aidaris Jimenez

Wiwik Watanabe

Donald J Kellerman

Katherine A Bender

Jeffrey B Alvarez

Joe Bogusky

Katherine Bender

An apparatus and method for establishing a global coordinate system to facilitate robotic assisted surgery. The coordinate system may be established using a combination of the robotic data, i.e., kinematics, and optical coherence tomographic images generated by an overhead optical assembly and a tool-based sensor. Using these components, the system may generate a computer-registered three-dimensional model of the patient's eye. In some embodiments, the system may also generate a virtual boundary within the coordinate system to prevent inadvertent injury to the patient.

Apparatus and method for a global coordinate system for use in robotic surgery

An endolumenal robotic system provides the surgeon with the ability to drive a robotically-driven endoscopic device to a desired anatomical position in a patient without the need for awkward motions and positions, while also enjoying improved image quality from a digital camera mounted on the endoscopic device.

System for robotic-assisted endolumenal surgery and related methods

8'-Hydroxy-Dihydroergotamine (8&#x2032;-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of migraine disorders using the compounds, compositions, dosage forms and administration techniques disclosed herein.

8'-hydroxy-dihydroergotamine compounds and compositions

Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HTand/or the 5-HTreceptor, without agonizing the 5-HTreceptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alphaand/or the alphareceptors using the compounds and compositions disclosed herein.

Fluoroergoline analogs

In one embodiment, the present invention is a method and apparatus for generating highly predictive blacklists. One embodiment of a method for generating a blacklist of network addresses for a user of a network includes collecting security log data from users of the network, the security log data identifying observed attacks by attack sources, assigning the attack sources to the blacklist based on a combination of the relevance each attack source to the user and the maliciousness of the attack source, and outputting the blacklist.

Method and apparatus for generating highly predictive blacklists

Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTreceptor and 5-HTreceptors the using the compounds and compositions disclosed herein.

Cabergoline derivatives

Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HTand/or the 5-HTreceptor, without agonizing the 5-HTreceptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alphaand/or the alphareceptors using the compounds and compositions disclosed herein.

Iso-ergoline derivatives

Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HTand/or the 5-HTreceptor, without agonizing the 5-HTreceptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alphaand/or the alphareceptors using the compounds and compositions disclosed herein. In other embodiments, provided herein are methods of agonizing dopaminergic Dreceptors and/or antagonizing or inhibiting activity of receptors such as the 5-HTreceptors using the compounds and compositions disclosed herein.

Neuromodulatory compounds

Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such as, for example, are methods for antagonizing the 5-HTreceptor without agonizing the 5-HTreceptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein such as, for example, are methods of agonizing the 5-HTreceptor using the compounds and compositions disclosed herein.

Methysergide derivatives

Methods for sterilizing a biocompatible hydrogel polymer are provided via treating the biocompatible hydrogel polymer with a supercritical COtreatment composition at a treatment pressure of about 4 MPa to about 30 MPa and a treatment temperature of about 5&#xb0; C. to about 75&#xb0; C. The supercritical COtreatment composition can be substantially pure COor may further include hydrogen peroxide (e.g., in an amount of about 10 ppm to about 1,000 ppm). In certain embodiments, the biocompatible hydrogel polymer can be treated with the supercritical COtreatment composition for about 30 minutes to about 5 hours. According to these methods, treating the biocompatible hydrogel polymer can kill about 90% or more of anyandpresent in the biocompatible hydrogel polymer.

Cold sterilization of tissue engineering scaffolds with compressed carbon dioxide

Growing community of inventors

Mountain View, CA, United States of America

Jian Zhang